Fleischmann, R. M., Genovese, M. C., Enejosa, J. V., Mysler, E., Bessette, L., Peterfy, C., . . . Song, I. (2019). Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis.
Chicago-stil citatFleischmann, Roy M., et al. "Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients With Rheumatoid Arthritis Over 48 Weeks With Switch to Alternate Therapy in Patients With Insufficient Response." Ann Rheum Dis 2019.
MLA-referensFleischmann, Roy M., et al. "Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients With Rheumatoid Arthritis Over 48 Weeks With Switch to Alternate Therapy in Patients With Insufficient Response." Ann Rheum Dis 2019.